Quantcast

Propecia Lawsuits: Next Status Conference in New Jersey Propecia Litigation Scheduled for March 7th, Bernstein Liebhard Reports

February 17, 2013

The Firm is currently evaluating Propecia lawsuits on behalf of men who suffered persistent sexual dysfunction allegedly due to Propecia.

New York, NY (PRWEB) February 17, 2013

Propecia lawsuits continue to move forward in a consolidated litigation underway in New Jersey Superior Court, Middlesex County, Bernstein Liebhard LLP reports. According to court records, the next Status Conference in the New Jersey Propecia litigation has been scheduled for March 7, 2013 at 10:00 a.m. There are currently 259 claims pending in the litigation, all of which allege plaintiffs suffered persistent sexual dysfunction due to their use of Propecia. (In Re: Propecia Litigation, No. 623, N.J. Super. Ct)

“We continue to hear from men who have suffered persistent sexual side effects after they stopped using Propecia. We look forward to progress in this litigation in the coming year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is actively investigating Propecia lawsuits on behalf of men who experienced long-lasting sexual side effects, allegedly due to Propecia.

Propecia Sexual Dysfunction

Propecia was approved by the U.S. Food & Drug Administration (FDA) in 1997 as a treatment for male pattern hair loss. Propecia prevents the conversion of testosterone to dihydrotestoterone (DHT) in the body, which has been implicated in the balding process. However, a growing body of research has pointed to an association between Propecia and persistent sexual dysfunction, including erectile dysfunction, loss of libido and orgasm disorder. In April 2012, the FDA announced that the Propecia label would be updated to advise that some men had experienced problems with libido, ejaculation and orgasms that continued after use of the drug was ended. Additional information was also added to the Propecia label describing reports of male infertility and poor semen quality that normalized or improved after use of the drug was stopped.*

In addition to the Propecia litigation underway in New Jersey, additional claims have been consolidated in a federal multidistrict litigation in U.S District Court, Eastern District of New York (Propecia (Finasteride) Product Liability Litigation — MDL No. 2331). Alleged victims of Propecia sexual dysfunction may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. The lawyers at Bernstein Liebhard LLP are offering free legal evaluations to Propecia users who suffered persistent sexual side effects. For more information about Propecia sexual dysfunction and depression, visit http://www.consumerinjurylawyers.com, or call (877) 779-1414.

*http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm299754.htm

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.consumerinjurylawyers.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpropecia-lawsuits/propecia-side-effects/prweb10437928.htm


Source: prweb



comments powered by Disqus